Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Cash & Equivalents (2016 - 2025)

Aspen Aerogels (ASPN) has disclosed Cash & Equivalents for 13 consecutive years, with $150.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 32.79% year-over-year to $150.7 million, compared with a TTM value of $150.7 million through Sep 2025, up 32.79%, and an annual FY2024 reading of $220.9 million, up 58.09% over the prior year.
  • Cash & Equivalents was $150.7 million for Q3 2025 at Aspen Aerogels, down from $167.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $281.3 million in Q4 2022 and bottomed at $17.2 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $139.8 million, with a median of $134.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 1091.57% in 2022, then tumbled 51.08% in 2024.
  • Year by year, Cash & Equivalents stood at $76.6 million in 2021, then skyrocketed by 267.45% to $281.3 million in 2022, then plummeted by 50.34% to $139.7 million in 2023, then surged by 58.09% to $220.9 million in 2024, then plummeted by 31.77% to $150.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ASPN at $150.7 million in Q3 2025, $167.6 million in Q2 2025, and $192.0 million in Q1 2025.